BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 27763812)

  • 1. Prostanoid Receptor Antagonist Effects on Intraocular Pressure, Supported by Ocular Biodisposition Experiments.
    Woodward DF; Wenthur SL; Rudebush TL; Fan S; Toris CB
    J Ocul Pharmacol Ther; 2016 Nov; 32(9):606-622. PubMed ID: 27763812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.
    Prasanna G; Carreiro S; Anderson S; Gukasyan H; Sartnurak S; Younis H; Gale D; Xiang C; Wells P; Dinh D; Almaden C; Fortner J; Toris C; Niesman M; Lafontaine J; Krauss A
    Exp Eye Res; 2011 Sep; 93(3):256-64. PubMed ID: 21376717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of prostanoid EP agonists on mouse intraocular pressure.
    Saeki T; Ota T; Aihara M; Araie M
    Invest Ophthalmol Vis Sci; 2009 May; 50(5):2201-8. PubMed ID: 19117925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey.
    Nilsson SF; Drecoll E; Lütjen-Drecoll E; Toris CB; Krauss AH; Kharlamb A; Nieves A; Guerra T; Woodward DF
    Invest Ophthalmol Vis Sci; 2006 Sep; 47(9):4042-9. PubMed ID: 16936121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent.
    Kirihara T; Taniguchi T; Yamamura K; Iwamura R; Yoneda K; Odani-Kawabata N; Shimazaki A; Matsugi T; Shams N; Zhang JZ
    Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):145-153. PubMed ID: 29332128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Responses of intraocular pressure and the pupil of feline eyes to prostaglandin EP1 and FP receptor agonists.
    Bhattacherjee P; Williams BS; Paterson CA
    Invest Ophthalmol Vis Sci; 1999 Nov; 40(12):3047-53. PubMed ID: 10549672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism and ocular tissue distribution of an antiglaucoma prostanoid, tafluprost, after ocular instillation to monkeys.
    Fukano Y; Kawazu K; Akaishi T; Bezwada P; Pellinen P
    J Ocul Pharmacol Ther; 2011 Jun; 27(3):251-9. PubMed ID: 21491995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular biology and ocular distribution of prostanoid receptors.
    Woodward DF; Regan JW; Lake S; Ocklind A
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S15-21. PubMed ID: 9154272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pharmacology of the DP/EP2 class prostaglandin AL-6598 and quantitative autoradiographic visualization of DP and EP2 receptor sites in human eyes.
    Sharif NA; Williams GW; Crider JY; Xu SX; Davis TL
    J Ocul Pharmacol Ther; 2004 Dec; 20(6):489-508. PubMed ID: 15684809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys.
    Yamane S; Karakawa T; Nakayama S; Nagai K; Moriyuki K; Neki S; Suto F; Kambe T; Hirota Y; Kawabata K
    Invest Ophthalmol Vis Sci; 2015 Apr; 56(4):2547-52. PubMed ID: 25788650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action.
    Sharif NA
    Curr Drug Targets; 2010 Aug; 11(8):978-93. PubMed ID: 20426763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EP3, but not EP2, FP, or TP prostanoid-receptor stimulation may reduce intraocular pressure.
    Waterbury LD; Eglen RM; Faurot GF; Cooper GF
    Invest Ophthalmol Vis Sci; 1990 Dec; 31(12):2560-7. PubMed ID: 2176184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug.
    Takagi Y; Nakajima T; Shimazaki A; Kageyama M; Matsugi T; Matsumura Y; Gabelt BT; Kaufman PL; Hara H
    Exp Eye Res; 2004 Apr; 78(4):767-76. PubMed ID: 15037111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models.
    Prasanna G; Fortner J; Xiang C; Zhang E; Carreiro S; Anderson S; Sartnurak S; Wu G; Gukasyan H; Niesman M; Nair S; Rui E; Lafontaine J; Almaden CD; Wells P; Krauss A
    Exp Eye Res; 2009 Nov; 89(5):608-17. PubMed ID: 19445930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraocular pressure effects of selective prostanoid receptor agonists involve different receptor subtypes according to radioligand binding studies.
    Woodward DF; Lawrence RA; Fairbairn CE; Shan T; Williams LS
    J Lipid Mediat; 1993; 6(1-3):545-53. PubMed ID: 8358015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostanoid EP4 receptor stimulation produces ocular hypotension by a mechanism that does not appear to involve uveoscleral outflow.
    Woodward DF; Nilsson SF; Toris CB; Kharlamb AB; Nieves AL; Krauss AH
    Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3320-8. PubMed ID: 19234340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostaglandin E2 inhibits mast cell-dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor.
    Säfholm J; Manson ML; Bood J; Delin I; Orre AC; Bergman P; Al-Ameri M; Dahlén SE; Adner M
    J Allergy Clin Immunol; 2015 Nov; 136(5):1232-9.e1. PubMed ID: 25962903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes.
    Sharif NA; McLaughlin MA; Kelly CR; Katoli P; Drace C; Husain S; Crosson C; Toris C; Zhan GL; Camras C
    Exp Eye Res; 2009 Mar; 88(3):386-97. PubMed ID: 18992242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical pharmacology of AL-12182, a new ocular hypotensive 11-oxa prostaglandin analog.
    Sharif NA; McLaughlin MA; Kelly CR; Xu S; Crider JY; Williams GW; Parker JL
    J Ocul Pharmacol Ther; 2006 Oct; 22(5):291-309. PubMed ID: 17076623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on the ocular hypotensive effects of prostaglandin F2 alpha ester prodrugs and receptor selective prostaglandin analogs.
    Woodward DF; Chan MF; Burke JA; Cheng-Bennett A; Chen G; Fairbairn CE; Gac T; Garst ME; Gluchowski C; Kaplan LJ
    J Ocul Pharmacol; 1994; 10(1):177-93. PubMed ID: 8207325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.